PhotonPharma Secures U.S. Patent for Novel Cancer Immunotherapy Using Photochemically-Inactivated Tumor Cells
核心洞察
PhotonPharma (搜索) received U.S. Patent No. 12,280,039 B2 for its Innocell™ (搜索) technology, which uses riboflavin and UV light to inactivate cancer cells while preserving tumor antigens for immunotherapy.
The patented approach demonstrated significant tumor growth inhibition, enhanced survival, and robust T-cell responses in preclinical studies across multiple animal models.
The company is initiating Phase I clinical trials targeting recurrent epithelial ovarian cancer, a disease affecting 20,890 women annually in the U.S. with a 51.6% five-year survival rate.
PhotonPharma (搜索), a Fort Collins-based biotechnology company, announced the issuance of U.S. Patent No. 12,280,039 B2 titled "Cancer Vaccine Compositions and Methods of Use Thereof" on April 22, 2025. The patent covers the company's proprietary Innocell™ (搜索) technology, which uses photochemically-inactivated cancer cells to create enhanced immunotherapy products for cancer treatment.
Innovative Photochemical Approach
The patented technology employs riboflavin (vitamin B2) as a photosensitizer that, when combined with UV light, inactivates cancer cells while preserving critical tumor antigens. This approach addresses a fundamental challenge in cancer immunotherapy: effectively presenting tumor antigens to the immune system to stimulate immune responses specific to each patient's tumor.
The Innocell™ (搜索) technology renders cancer cells completely incapable of replication while maintaining their antigenic properties and preserving cell metabolism. These altered cells can stimulate immune responses that have been demonstrated to target tumor cell destruction in preclinical studies, according to the patent documentation.
Preclinical Validation Results
The patent includes extensive preclinical validation demonstrating significant therapeutic potential across multiple parameters. In animal models, the technology showed significant reduction in tumor growth rates compared to controls. Efficacy studies revealed extended survival times in treated groups, while immunological assessments confirmed robust T-cell responses and immunological memory formation.
"This patent issuance validates our innovative approach to cancer immunotherapy and strengthens our intellectual property portfolio as we advance toward clinical trials," said Alan Rudolph, Ph.D., PhotonPharma (搜索) board member. "Our technology has the potential to transform recurrent ovarian cancer treatments, offering patients a safer and more effective option."
Clinical Development Focus
PhotonPharma (搜索) is initiating Phase I trials targeting recurrent epithelial ovarian cancer patients. This focus addresses a significant medical need, as ovarian cancer will impact 20,890 women in the U.S. with 12,730 deaths in 2025 alone, according to National Cancer Institute data. The average five-year relative survival rate stands at 51.6% based on 2015-2021 data.
Manufacturing and Market Advantages
The photochemical inactivation process offers several manufacturing advantages, including rapid processing, reproducibility, and suitability for clinical-scale production. The technology demonstrates broad applicability across multiple cancer types and stages, positioning it as a versatile platform for cancer immunotherapy development.
The global cancer immunotherapy market is projected to reach between $231-277 billion by 2031, with compound annual growth rates of 11.9% to 13.6%, driven by increasing cancer incidence and growing adoption of immunotherapy approaches. This patent positions PhotonPharma (搜索) within this expanding market segment for next-generation cancer immunotherapy development.
PhotonPharma (搜索)'s lead product Innocell™ (搜索) remains an investigational therapy that has not received FDA approval, and its safety and efficacy have not been established. The company focuses on developing innovative cancer therapies that leverage the immune system to fight disease, with an emphasis on personalized medicine approaches for solid organ tumors.